Cargando…
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy
CYP3A ranks among the most abundant cytochrome P450 enzymes in the liver, playing a dominant role in metabolic elimination of clinically used drugs. A main member in CYP3A family, CYP3A4 expression and activity vary considerably among individuals, attributable to genetic and non-genetic factors, aff...
Autores principales: | Wang, Danxin, Sadee, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901424/ https://www.ncbi.nlm.nih.gov/pubmed/24466438 http://dx.doi.org/10.3390/jpm2040175 |
Ejemplares similares
-
Genotyping panel for assessing response to cancer chemotherapy
por: Dai, Zunyan, et al.
Publicado: (2008) -
Transcription Factors and ncRNAs Associated with CYP3A Expression in Human Liver and Small Intestine Assessed with Weighted Gene Co-Expression Network Analysis
por: Huang, Huina, et al.
Publicado: (2022) -
A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples
por: Collins, Joseph M., et al.
Publicado: (2023) -
Genome-wide microRNA profiles identify miR-107 as a top miRNA associating with expression of the CYP3As and other drug metabolizing cytochrome P450 enzymes in the liver
por: Tantawy, Marwa, et al.
Publicado: (2022) -
Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits
por: Pinsonneault, Julia K., et al.
Publicado: (2017)